NVSNovartis PharmaceuticalsSigning up patients
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Hematologic Malignancy · Solid Tumor · Advanced Malignancies
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 50 (planned)
- Started
- Aug 13, 2024
- Main results expected
- Jun 2, 2027
- Fully finished
- Jun 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Treatment-emergent adverse events (TEAEs) and serious TEAEs
Measured over: 5 years
Survival Follow-up
Measured over: 5 years
Duration of Response (DoR)
Measured over: 5 years
Progression-free survival (PFS)
Measured over: 5 years
Leukemia-free survival (LFS)
Measured over: 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06401356 · record last updated 2026-06-11 · checked 2026-11-09 15:47 UTC